ARS Pharmaceuticals(US:SPRY) Globenewswire·2025-08-13 11:00Core Insights - ARS Pharmaceuticals reported $15.7 million in total revenue for Q2 2025, with $12.8 million coming from neffy U.S. net product revenue, indicating strong growth driven by increased payor access and a national DTC campaign [1][5][6] - The company achieved 93% commercial coverage for neffy, with a streamlined prior authorization process leading to high approval rates, positioning neffy as a preferred option for allergic reactions [1][6][8] - neffy has expanded its global footprint with EURneffy approved in the U.K. and launched in Germany, marking significant milestones in the company's international strategy [1][9][10] Financial Performance - Total revenue for Q2 2025 was $15.7 million, including $12.8 million from neffy sales, $2.6 million in milestone revenue from ALK-Abelló A/S, and $0.3 million in supply revenue [5][32] - R&D expenses were $4.0 million, primarily for clinical trials and development expenses related to neffy [5][32] - SG&A expenses reached $54.3 million, reflecting significant investment in marketing and commercialization efforts for neffy [5][32] - The net loss for Q2 2025 was $44.9 million, or $0.46 per share, with cash reserves of $240.1 million as of June 30, 2025, supporting operations for at least the next three years [5][32] Commercial Launch and Growth - neffy prescription growth increased approximately 180% from Q1 to Q2 2025, driven by effective sales execution and marketing strategies [4][6] - The DTC campaign significantly raised consumer awareness of neffy from 20% to 49% by late July 2025, with expectations for continued momentum [8] - Over 9,700 healthcare providers have prescribed neffy, a 73% increase since April 2025, indicating strong adoption among high-prescribing HCPs [6][8] Global Expansion - EURneffy was approved in the U.K. in July 2025 and launched in Germany in June 2025, with further regulatory approvals anticipated in Canada, Japan, Australia, and China by 2026 [9][10][11] - The company is also pursuing a Phase 2b clinical trial for neffy in treating chronic spontaneous urticaria, expanding its product's indications [11]